研究报告 |
|
|
|
|
p300通过homeobox结构域增强Nanog的转录激活活性 |
郭允倩1,陈默2,马天骅2,裴端卿3 |
1. 清华大学医学院生物膜与膜生物工程国家重点实验室 北京 100084
2.中国科学院广州生物医药与健康研究院再生生物学国家重点实验室 广州 510663
3. 北京林业大学林木育种国家工程实验室 林木、花卉遗传育种教育部重点实验室 北京 100083 |
|
P300 Enhances Nanog Transcriptional Activity Through the Homeobox Domain |
1.State Key Laboratory of Biomembrane and Membrane Biotechnology,Institutes of Biomedicine,School of Medicine,Tsinghua University,Beijing 100084,China
2.Key Laboratory of Regenerative Biology,Guangzhou Institute of Biomedicine and Health,Chinese Academy of Sciences,Guangzhou 510663,China
3.National Engineering Laboratory for Tree Breeding,Key Laboratory of Genetics and Breeding in Forest Trees and Ornamental Plants,Ministry of Education,Beiming Forestry University,Beijing 100083,China. |
[1] |
Boyer L A, Lee T I, Cole M F, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell, 2005,122:947~956
|
[2] |
Pan G J, Li J, Zhou Y L, et al. A negative feedback loop of transcription factors that controls stem cell pluripotency and selfrenewal. Faseb J, 2006,20:1730
|
[3] |
Niwa H, Burdon T, Chambers I, et al. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Gene Dev, 1998,12:2048~2060
|
[4] |
Chambers I, Colby D, Robertson M, et al. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell, 2003,113:643~655
|
[5] |
Mitsui K, Tokuzawa Y, Itoh H, et al. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell, 2003,113:631~642
|
[6] |
Silva J, Chambers I, Pollard S, et al. Nanog promotes transfer of pluripotency after cell fusion. Nature, 2006,441:997~1001
|
[7] |
Yu J, Vodyanik M A, SmugaOtto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science, 2007,318:1917~1920
|
[8] |
Goodman R H, Smolik S. CBP/p300 in cell growth, transformation, and development. Genes & Development, 2000,14:1553~1577
|
[9] |
Shiama N. The p300/CB Pfamily: integrating signals with transcription factors and chromatin. Trends in Cell Biology, 1997,7:230~236
|
[10] |
Giles R H, Peters D J, Breuning M H. Conjunction dysfunction: CBP/p300 in human disease. Trends Genet, 1998,14:178~183
|
[11] |
Giordano A, Avantaggiati M L. p300 and CBP: partners for life and death. Journal of Cellular Physiology, 1999,181:218~230
|
[12] |
Grossman S R. p300/CBP/p53 interaction and regulation of the p53 response. European Journal of Biochemistry / FEBS, 2001,268:2773~2778
|
[13] |
Gu W, Roeder R G. Activation of p53 sequencespecific DNA binding by acetylation of the p53 C-terminal domain. Cell,1997,90:595~606
|
[14] |
Liu L, Scolnick D M, Trievel R C, et al. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Molecular and Cellular Biology, 1999,19:1202~1209
|
[15] |
Sakaguchi K, Herrera J E, Saito S, et al. DNA damage activates p53 through a phosphorylationacetylation cascade. Genes & Development, 1998,12:2831~2841
|
[16] |
Wang J L, Rao S, Chu J L, et al. A protein interaction network for pluripotency of embryonic stem cells. Nature, 2006,444:364~368
|
[17] |
Pan G J, Pei D Q. Identification of two distinct transactivation domains in the pluripotency sustaining factor nanog. Cell Res, 2003,13:499~502
|
[18] |
Pan G J, Pei D Q. The stem cell pluripotency factor NANOG activates transcription with two unusually potent subdomains at its C terminus. J Biol Chem, 2005,280:1401~1407
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|